Core Insights - MetaVia Inc. announced the acceptance of two abstracts for poster presentations at ObesityWeek® 2025, focusing on DA-1726, a novel dual oxyntomodulin analog agonist targeting cardiometabolic diseases [1][3]. Company Overview - MetaVia Inc. is a clinical-stage biotechnology company dedicated to transforming cardiometabolic diseases, currently developing DA-1726 for obesity treatment and Vanoglipel (DA-1241) for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [4]. Product Details - DA-1726 is a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), administered once weekly subcutaneously, aimed at weight loss through appetite reduction and increased energy expenditure [3]. - In pre-clinical studies, DA-1726 showed superior weight loss compared to semaglutide and cotadutide, while also preserving lean body mass and demonstrating improved lipid-lowering effects compared to survodutide [3]. - The Phase 1 multiple ascending dose trial indicated that the 32 mg dose of DA-1726 has best-in-class potential for weight loss, glucose control, and waist circumference reduction [3][4]. Upcoming Presentations - The poster presentations will take place on November 4, 2025, at Exhibit Hall A1, featuring topics on the safety, tolerability, and pharmacokinetics of DA-1726, as well as its potential as a therapy for obesity and related metabolic disorders [6].

Company Overview - Veru Inc. is a late clinical stage biopharmaceutical company focused on developing innovative medicines for cardiometabolic and inflammatory diseases [2] - The company's drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin [2] Enobosarm Obesity Program - Enobosarm is being developed as a next-generation drug to enhance fat loss while preserving lean mass, particularly in older patients receiving semaglutide for chronic weight management [3][4] - The Phase 2b QUALITY clinical study showed positive topline and safety results, with participants losing an average of 11.88 lbs during the active weight loss period [4] - After discontinuation of semaglutide, the placebo group regained 43% of lost body weight, while the enobosarm 3mg and 6mg groups regained only 1.41% (2.73 lbs) and 2.87% (5.29 lbs) respectively, demonstrating a significant reduction in weight regain [4][5] - Enobosarm monotherapy preserved more than 100% of lean mass compared to the placebo group, which experienced a loss of lean mass [5][6] Sabizabulin Atherosclerosis Inflammation Program - Sabizabulin is being explored for the treatment of inflammation in atherosclerotic cardiovascular disease, addressing a significant unmet medical need [8][9] - The drug has shown broad anti-inflammatory activity in previous clinical studies, with a safety database consisting of 266 dosed patients [8][9] - The company believes that combining sabizabulin with statin therapy could effectively reduce inflammation and slow the progression of atherosclerotic cardiovascular disease [8][9] Upcoming Events - Veru Inc. will participate in one-on-one meetings and a fireside chat presentation with investors at the 2025 BTIG Virtual Biotech Conference on July 29-30, 2025 [1]